文献速递妇科

重新审视米兰宫颈癌研究:在化疗时代原始结论是否依然成立

Revisiting Milan cervical cancer study: Do the original findings hold in the era of chemotherapy?
PubMed 文献 · Gynecol Oncol · 2016-11-26

基于美国国家癌症数据库(NCDB)2004至2013年5478例早期宫颈癌(IB-IIA)患者,比较非手术组(n=1980)与手术组(n=3498)的生存结局。中位随访46个月,倾向评分分析后两组5年总生存率相似(73.8% vs 75.7%,p=0.619)。作者认为手术(术后辅助放疗或放化疗)与根治性放疗(联合或不联合化疗)生存等效,并呼吁开展前瞻性研究。

要点

  • 倾向评分匹配后,非手术组与手术组5年总生存率分别为73.8%与75.7%,差异无统计学意义(p=0.619)。
  • 多因素分析显示高Charlson合并症评分、IIA期、较大肿瘤、淋巴结阳性及高级别病变为预后不良的显著预测因素。
  • 作者认为手术(术后辅助放疗或放化疗)与根治性放疗(联合或不联合化疗)生存等效。

核心结论

  • 作者分析提示,手术(术后辅助放疗或放化疗)与根治性放疗(联合或不联合化疗)可获得等效生存。
  • 作者提出需开展前瞻性研究以在化疗时代确立该范式。

研究设计与样本

  • 基于美国国家癌症数据库(NCDB)的队列研究,纳入2004至2013年诊断为早期宫颈癌(IB-IIA)的5478例患者。
  • 按主要治疗方式分为非手术组(n=1980)与手术组(n=3498)。
  • 采用倾向评分分析校正协变量不平衡以构建匹配良好的患者队列,并评估总生存及比例回归模型。

主要发现

  • 中位随访46个月,倾向评分分析后两组5年总生存率相似:非手术组73.8% vs 手术组75.7%(p=0.619)。
  • 多因素分析中,高Charlson合并症评分、IIA期疾病、较大肿瘤尺寸、淋巴结阳性及高级别病变为预后不良的显著预测因素。
  • 多因素分析中,年龄较大与治疗方式并非显著预测因素。

局限性

  • 作者提出需开展前瞻性研究以在化疗时代确立该范式。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The primary treatment of early stage cervical carcinoma (IB-IIA) is either surgery or radiation therapy based on the pivotal Milan randomized study published twenty years ago. In the presence of high-risk features, the gold standard treatment is concurrent chemotherapy and radiation therapy (CRT) whether it is the in the postoperative or the definitive setting. Using the National Cancer Data Base (NCDB), the goal of our study is to compare the outcomes of surgery and radiation therapy in the chemotherapy era. METHODS: Between 2004 and 2013, 5478 patients diagnosed with early stage cervical cancer were divided into 2 groups based on their primary treatment: non-surgical (n=1980) and surgical groups (n=3498). The distribution of patient/tumor characteristics and treatment variables with their relation to overall survival and proportional regression models were assessed to investigate the superiority of one approach over the other. Propensity score analysis adjusted for imbalance of covariates to create a well-matched-patient cohort. FINDINGS: At 46months median follow-up, the 5-year overall survival was similar between both groups (73·8% vs. 75.7%; p=0.619) after applying propensity score analysis. On multivariate analysis, high Charlson comorbidity score, stage IIA disease, larger tumor size, positive lymph nodes and high-grade disease were significant predictors of poor outcome while older age and treatment approach were not. INTERPRETATION: Our analysis suggests that surgery (followed by adjuvant RT or CRT) and definitive radiotherapy (with or without chemotherapy) result in equivalent survival. Prospective studies are warranted to establish this paradigm in the chemotherapy era.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Ross Green W, Hathout L, Khan AJ, et al. Revisiting Milan cervical cancer study: Do the original findings hold in the era of chemotherapy? Gynecol Oncol. 2016. PMID: 27899201. doi:10.1016/j.ygyno.2016.11.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。